Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 2.156 5-летний Импакт фактор: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 30, 2020 Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v21.i1.10
pages 1-12

Heparan Sulfate-based Treatments for Regenerative Medicine

Bina Rai
Institute of Medical Biology, A*STAR, Singapore
Victor Nurcombe
Institute of Molecular and Cell Biology; and Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Simon M. Cool
Institute of Molecular and Cell Biology; and Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Краткое описание

This review summarizes the emerging strategies that exploit the glycosaminoglycan sugar, heparan sulfate (HS), either as a substitute for, or as a supplement to growth factor (GF) therapy for regenerative medicine. Excluding autograft, the administration of GFs is currently the most effective treatment for critical bone repair and restoration. However, major hurdles in the clinical development of GF therapies include the high cost, the unwanted side effects, and the toxicity associated with the physiological overdosing required to achieve a successful outcome. These drawbacks may be overcome with the application of particular HS fractions that have been optimized to bind, recruit and enhance the biological activity of endogenous GF at the site of injury. Three HS-based treatments are discussed here: first, the single, localized, and sustained delivery of HS as a stand-alone therapeutic agent; then, the inclusion of an HS component within a delivery device so as to stabilize and potentiate the bioactivity of the incorporated GF; and finally, the growing use of HS mimetics, particularly for bone repair.

Ключевые слова: heparan sulfate, bone, growth factor, delivery

Articles with similar content:

Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst
Fibrin Sealant Tissue Adhesive−Review and Update
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 3
Roshan Prabhu, William D. Spotnitz
Scaffolds: A Novel Carrier and Potential Wound Healer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 4
Tarun Garg, Chetan Chaudhary
Scaffold: A Novel Carrier for Cell and Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 1
Saahil Arora , R. S. R. Murthy, Onkar Singh, Tarun Garg
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy
Critical Reviews™ in Immunology, Vol.39, 2019, issue 2
David M. Kranz, Preeti Sharma